Next Article in Journal
Metabolic Changes in Early-Stage Non–Small Cell Lung Cancer Patients after Surgical Resection
Next Article in Special Issue
Targeted Liposomal Chemotherapies to Treat Triple-Negative Breast Cancer
Previous Article in Journal
Blockade of HVEM for Prostate Cancer Immunotherapy in Humanized Mice
Previous Article in Special Issue
Nature-Inspired Nanoparticles as Paclitaxel Targeted Carrier for the Treatment of HER2-Positive Breast Cancer
 
 
Article

Albumin-Based Nanoparticles for the Delivery of Doxorubicin in Breast Cancer

Instituto Madrileño de Estudios Avanzados en Nanociencia (IMDEA Nanociencia), Faraday 9, 28049 Madrid, Spain
*
Author to whom correspondence should be addressed.
Academic Editors: Ana Isabel Torres-Suárez and Ana Isabel Fraguas-Sánchez
Cancers 2021, 13(12), 3011; https://doi.org/10.3390/cancers13123011
Received: 1 June 2021 / Revised: 11 June 2021 / Accepted: 14 June 2021 / Published: 16 June 2021
(This article belongs to the Special Issue Development of Innovative Formulations for Breast Cancer Chemotherapy)
Doxorubicin (Dox) is a chemotherapeutic agent usually employed for the treatment of breast cancer. However, its use is limited because of the toxicities associated, and hence a proper delivery vehicle is necessary. In this sense, albumin-based nanocarriers are in the limelight for the successful delivery of chemotherapeutics because of safety, biocompatibility, and specific cancer-targeting properties. Herein, we have developed a nanocarrier system based on albumin, which selectively affects the tumor cells, and hence can revolutionize breast cancer therapy. The developed nanoparticles could be further used for the delivery of other hydrophobic drugs like SN38, which broadens the use of this system in the treatment of breast cancer.
Albumin-based nanoparticles are an emerging platform for the delivery of various chemotherapeutics because of their biocompatibility, safety, and ease of surface modification for specific targeting. The most widely used method for the preparation of albumin nanoparticles is by desolvation process using glutaraldehyde (GLU) as a cross-linker. However, limitations of GLU like toxicity and interaction with drugs force the need for alternative cross-linkers. In the present study, several cross-linking systems were evaluated for the preparation of Bovine Serum Albumin (BSA) nanoparticles (ABNs) encapsulating Doxorubicin (Dox). Based on the results obtained from morphological characterization, in vitro release, and therapeutic efficacy in cells, N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP)-modified ABNs (ABN-SPDP) was chosen. Since ABN-SPDP are formed with disulfide linkage, the drug release is facilitated under a highly reducing environment present in the tumor sites. The cytotoxicity studies of those ABN-SPDP were performed in three different breast cell lines, highlighting the mechanism of cell death. The Dox-encapsulated ABN-SPDP showed toxicity in both the breast cancer cells (MCF-7 and MDA-MB-231), but, remarkably, a negligible effect was observed in non-tumoral MCF-10A cells. In addition to the hydrophilic Dox, this system could be used as a carrier for hydrophobic drugs like SN38. The system could be employed for the preparation of nanoparticles based on human serum albumin (HSA), which further enhances the feasibility of this system for clinical use. Hence, the albumin nanoparticles developed herein present an excellent potential for delivering various drugs in cancer therapy. View Full-Text
Keywords: bovine serum albumin (BSA); N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP); doxorubicin (Dox); breast cancer; cross-linker bovine serum albumin (BSA); N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP); doxorubicin (Dox); breast cancer; cross-linker
Show Figures

Figure 1

MDPI and ACS Style

Prajapati, R.; Garcia-Garrido, E.; Somoza, Á. Albumin-Based Nanoparticles for the Delivery of Doxorubicin in Breast Cancer. Cancers 2021, 13, 3011. https://doi.org/10.3390/cancers13123011

AMA Style

Prajapati R, Garcia-Garrido E, Somoza Á. Albumin-Based Nanoparticles for the Delivery of Doxorubicin in Breast Cancer. Cancers. 2021; 13(12):3011. https://doi.org/10.3390/cancers13123011

Chicago/Turabian Style

Prajapati, Rama, Eduardo Garcia-Garrido, and Álvaro Somoza. 2021. "Albumin-Based Nanoparticles for the Delivery of Doxorubicin in Breast Cancer" Cancers 13, no. 12: 3011. https://doi.org/10.3390/cancers13123011

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop